MRNA vs VRDN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

MRNA is the larger of the two ($79.58B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 1.17). VRDN is the smaller challenger ($3.48B), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, VRDN fits: analysts expect its revenue to rise 324% next year, against 11% for MRNA. If you believe MRNA's main driver (Respiratory franchise beyond COVID) pays off sooner, MRNA fits.

MRNA vs VRDN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricMRNAVRDNWhat it tells you
Market cap$79.58B$3.48BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-46.96-14.83Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.171.07Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range67% of range83% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book11.627.21How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how MRNA and VRDN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MRNA and VRDN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MRNA and VRDN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Moderna (MRNA) do?

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

What does Viridian Therapeutics (VRDN) do?

Viridian Therapeutics (Nasdaq: VRDN) is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging (proptosis) and double vision (diplopia). Its lead drug, Lumvoa (veligrotug-vvze), is an intravenous anti-IGF-1R antibody that the FDA approved in June 2026 for both active and chronic TED, based on the THRIVE and THRIVE-2 phase 3 trials. The company is also developing subcutaneous elegrobart (an autoinjector TED candidate with positive REVEAL-1 and REVEAL-2 phase 3 data and a BLA filing on track for the first quarter of 2027) and an earlier-stage FcRn portfolio (VRDN-006 and VRDN-008).

Full VRDN guide

MRNA vs VRDN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.
  • VRDN drivers: Lumvoa launch and TED market share; Subcutaneous elegrobart pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. For VRDN, viridian is a newly commercial biotech with early product revenue (~$24.7 million in its first full quarter) and quarterly net losses around $100 million (~$101 million in Q3 2026, ~$398 million over the trailing twelve months), so its valuation depends heavily on future sales that have not yet materialized.

MRNA or VRDN: which should you pick?

If the story you believe is MRNA's (Respiratory franchise beyond COVID), MRNA is the more direct way to own it; if it is VRDN's (Lumvoa launch and TED market share), VRDN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MRNA and VRDN guides.

MRNA vs VRDN: the full fundamentals

MRNA. MRNA trades on pipeline potential rather than current earnings: it is loss-making over the trailing year, revenue is far below its pandemic peak, and P/E is not meaningful. What changed in 2026 is the price of that option, with the stock up about 538% year to date to roughly 32 times trailing sales after the August Phase 3 melanoma success, even after a 17% drop on higher spending guidance in November. The 19 analysts Yahoo Finance tracks have a mean target near $165, under the $196.74 close, and consensus sees a loss of about $4.45 per share in 2027 on about $2.69 billion of revenue.

VRDN. As of November 20, 2026, Viridian carried a roughly $3.5 billion market cap against ~$26 million of trailing revenue, nearly all of it from Lumvoa's first full quarter, so the ~132x price-to-sales figure says little about the launch. The valuation rests on expectations for TED sales (consensus ~$50 million in Q4 2026 and ~$323 million in 2027) and on a cash balance near $955 million that funds continuing losses.

Headline figures (approximate, November 2026): MRNA shows market cap ~$80 billion, revenue (ttm) ~$2.5 billion, q3 2026 revenue ~$1.31 billion vs ~$892 million consensus, net income (ttm) ~-$2.8 billion; VRDN shows revenue (ttm) ~$26M, almost all Lumvoa sales in Q3 2026, lumvoa net product revenue (q3 2026) ~$24.7M vs ~$4.7M consensus revenue, net loss (ttm) ~$398M; Q3 2026 ~$101M, eps (q3 2026) -$0.81 vs -$1.02 consensus.

The bottom line: MRNA vs VRDN

MRNA and VRDN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined MRNA and VRDN exposure against your real portfolio. It is not an investment adviser.

Wondering how MRNA or VRDN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Moderna

Ask Walnut's AI anything about MRNA and see how it fits what you own.

FAQ

What is the difference between MRNA and VRDN?

+

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. Viridian Therapeutics (Nasdaq: VRDN) is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging (proptosis) and double vision (diplopia). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is MRNA or VRDN the better stock?

+

Neither is universally better. MRNA is the larger incumbent; VRDN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, MRNA or VRDN?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both MRNA and VRDN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of MRNA vs VRDN?

+

MRNA: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed. Valuation risk is now acute: at about $80 billion the company trades near 32 times trailing sales, and the 19 analysts Yahoo Finance tracks have a mean target near $165 with a Hold rating, below the November 20 close (Jefferies cut its target to $215 from $230 on November 18). Higher spending is a newer risk: guidance for about $4 billion of 2027 cash costs sent the shares down about 17% in a week in November 2026, and debt has risen to about $4.2 billion. A delayed FDA filing or a regulatory setback for intismeran could reverse much of the gain. Walnut is not an investment adviser. VRDN: Viridian is a newly commercial biotech with early product revenue (~$24.7 million in its first full quarter) and quarterly net losses around $100 million (~$101 million in Q3 2026, ~$398 million over the trailing twelve months), so its valuation depends heavily on future sales that have not yet materialized. Lumvoa faces direct competition from Amgen's Tepezza, an entrenched incumbent that is also developing a subcutaneous formulation, and launch uptake, pricing, reimbursement, and physician adoption are all uncertain. The company is concentrated in thyroid eye disease, a rare-disease market, so any safety signal, slow launch, or competitive setback would weigh heavily. Pipeline programs like elegrobart and the FcRn portfolio carry clinical and regulatory risk, and continued losses could eventually require additional capital that dilutes shareholders. The stock has already shown that sensitivity, trading in a 52-week range of roughly $13 to $34 and gaining ~37% in the single month after the Q3 report, which raises the bar for the next quarters. Broad payer coverage is only targeted six to nine months after launch, and management has said it is too early to confirm a sustained trend.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MRNA or VRDN; figures are approximate and dated (as of November 2026). Verify current data before investing.